What is LOPJLB’s current signal on HLVX?

LOPJLB’s latest quantitative signal on HilleVax, Inc. (HLVX) is BUY in a BULL regime. Signals are updated daily.

What market regime is HLVX in?

HilleVax, Inc. (HLVX) is currently classified in the BULL HMM market regime on LOPJLB.

HilleVax, Inc. (HLVX)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$2.09+0.00%Close

BUYBULL · day 18

RANGE

DATA 2025-09-18

LOPJLB.COM

OHLCEMALEVELSSTOPFLIP52WSIGNALSBUYSELLEXHEXH ZONE

Key stats

Market cap: $105M
Beta: 0.77

P/E (TTM): -0.70

1W: +0.00%
1M: +1.46%

vs SPY 1W: -1.16%
vs SPY 1M: -1.54%

Industry peers

FMP comparable companies · ranked by market cap

TRMLTourmaline Bio, Inc.$1.2B$47.98

Prediction markets

Kalshi · Polymarket · … linked

Full prediction markets →

Loading markets…

Company

HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent…

Employees: 14
Headquarters: US
Founded: 2022
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares out: 50.1M
Float: 45.4%

xoma.com ↗

Key executives

Robert Hershberg — Co-Founder, President, Chief Executive Officer & Chairman of the Board

Aditya Kohli — Co-Founder & Director

Shane A. Maltbie — Chief Financial Officer & Treasurer

SEC filings

EDGAR · CIK 18880120 · HLVX

Analyst consensus

Hold

Bullish116.7%

Neutral583.3%

Bearish00.0%

L $30.00Avg $32.00H $34.00

Target$32.00+1431.10%

Last$2.09

FAQ

What is LOPJLB’s current signal on HLVX?: LOPJLB’s latest quantitative signal on HilleVax, Inc. (HLVX) is BUY in a BULL regime. Signals are updated daily.
What market regime is HLVX in?: HilleVax, Inc. (HLVX) is currently classified in the BULL HMM market regime on LOPJLB.
What does HilleVax, Inc. (HLVX) do?: HilleVax, Inc. is a clinical-stage biopharmaceutical enterprise specializing in the creation and market introduction of innovative vaccines. The company's lead investigational product is HIL-214, a vaccine candidate utilizing virus-like particles, which aims to prevent moderate-to-severe acute gastroenteritis resulting from norovirus infections. Its corporate headquarters are located in Boston,…

Key stats

Industry peers

Prediction markets

Company news

FAQ